August 4, 2022

Novavax COVID-19 Vaccine Potential Alternative for mRNA Vaccine

With many pharmacies preparing to offer the newly authorized Novavax COVID-19 vaccine, pharmacists have another tool to reassure vaccine-hesitant adults. Some potential recipients have expressed concerns about the relatively novel messenger RNA (mRNA) technology used in the Pfizer-BioNTech and Moderna vaccines. The protein subunit form of vaccine—the Novavax technology—has been used in the U.S. for more than 30 years, including in influenza vaccines. Read more.


Androgen-Deprivation Therapy Raises Risk of Cardiovascular Death

Recent studies have cautioned that androgen-deprivation therapy could have adverse effects on the hearts of prostate cancer patients. A recent population study is raising concerns that hormone therapy for prostate cancer increases the risk of cardiovascular disease–related death, chiefly in older men who are most likely to be diagnosed with the cancer. Learn more about the results of this study.

Pharmacists as Deprescribing Coordinators Reduced Anticholinergic Use

Widely prescribed anticholinergics can harm memory, alertness, and planning skills in some older adults. A new study finds that pharmacists can effectively facilitate deprescribing of the drugs used for depression, urinary incontinence, and many other conditions. Learn more about information on the effort to promote pharmacist-centric delivery models to make sure the safest drugs are used.


Pharmacogenomic Testing Yields Positive Results for MDD Patients

The good news is that pharmacogenomic testing was generally positive for patients with major depressive disorder (MDD), resulting in potentially more effective prescribing, according to a recently published large study in the Journal of the American Medical Association. The bad news, however, is that researchers were not able to identify significant effects on symptom remission. Read more.

Facebook   Twitter   USP Google App   USP itunes App
U.S. Pharmacist
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Advertisement Advertisement